Mouse Anti-CARD11 Recombinant Antibody (CBFYC-0811) (CBMAB-C0866-FY)

Name: Mouse Anti-CARD11 Recombinant Antibody (CBFYC-0811)
SKU: CBMAB-C0866-FY
Rating: 5 (1 reviews)

See all CARD11 antibodies

Compare Online Inquiry

Published Data

Mouse Anti-CARD11 Recombinant Antibody (CBFYC-0811) (CBMAB-C0866-FY) in Immunoblot and IP

The PDZ-SH3 region of CARMA1 binds HOIP. A similar analysis to that in Figure 2D was performed, using WT and various mutants of FLAG-CARMA1 and Myc-HOIP. ...View More

Oikawa, D., Hatanaka, N., Suzuki, T., & Tokunaga, F. (2020). Cellular and mathematical analyses of LUBAC involvement in T cell receptor-mediated NF-κB activation pathway. Frontiers in Immunology, 11, 601926.

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBFYC-0811

Application

WB, IP, IF, ELISA, IHC-P

Immunogen

Amino acids 848-1147 mapping at the C-terminus of CARD 11 of human origin.

Host Species

Mouse

Specificity

Human, Mouse, Rat

Antibody Isotype

IgG1, κ

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Application	Note
WB	1:100-1:1,000
IP	1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
ELISA	1:100-1:1,000
IF(ICC)	1:50-1:500
IHC-P	1:50-1:500

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, 0.1% gelatin

Preservative

< 0.1% sodium azide

Concentration

0.2 mg/ml

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at-20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

Caspase Recruitment Domain Family Member 11

Introduction

The protein encoded by this gene belongs to the membrane-associated guanylate kinase (MAGUK) family, a class of proteins that functions as molecular scaffolds for the assembly of multiprotein complexes at specialized regions of the plasma membrane. This protein is also a member of the CARD protein family, which is defined by carrying a characteristic caspase-associated recruitment domain (CARD). This protein has a domain structure similar to that of CARD14 protein. The CARD domains of both proteins have been shown to specifically interact with BCL10, a protein known to function as a positive regulator of cell apoptosis and NF-kappaB activation. When expressed in cells, this protein activated NF-kappaB and induced the phosphorylation of BCL10.

Entrez Gene ID

Human	84433
Mouse	108723
Rat	100363332

UniProt ID

Human	Q9BXL7
Mouse	Q8CIS0

Alternative Names

Caspase Recruitment Domain Family Member 11; Bcl10-Interacting Maguk Protein 3; CARD-Containing MAGUK Protein 1; Carma 1; CARMA1; Caspase Recruitment Domain-Containing Protein 11; Caspase Recruitment Domain Family, Member 11

Function

Adapter protein that plays a key role in adaptive immune response by transducing the activation of NF-kappa-B downstream of T-cell receptor (TCR) and B-cell receptor (BCR) engagement (PubMed:11278692, PubMed:11356195, PubMed:12356734).
Transduces signals downstream TCR or BCR activation via the formation of a multiprotein complex together with BCL10 and MALT1 that induces NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways (PubMed:11356195).
Upon activation in response to TCR or BCR triggering, CARD11 homooligomerizes to form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerization of BCL10 and subsequent recruitment of MALT1: this leads to I-kappa-B kinase (IKK) phosphorylation and degradation, and release of NF-kappa-B proteins for nuclear translocation (PubMed:24074955).
Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner (PubMed:17287217).
Promotes linear ubiquitination of BCL10 by promoting the targeting of BCL10 to RNF31/HOIP (PubMed:27777308).
Stimulates the phosphorylation of BCL10 (PubMed:11356195).
Also activates the TORC1 signaling pathway (PubMed:28628108).

Biological Process

B cell differentiation Source: Ensembl
B cell proliferation Source: Ensembl
Fc-epsilon receptor signaling pathway Source: Reactome
Homeostasis of number of cells Source: Ensembl
I-kappaB kinase/NF-kappaB signaling Source: UniProtKB
Positive regulation of B cell proliferation Source: Ensembl
Positive regulation of I-kappaB kinase/NF-kappaB signaling Source: UniProtKB
Positive regulation of interleukin-2 production Source: UniProtKB
Positive regulation of NF-kappaB transcription factor activity Source: UniProtKB
Positive regulation of T cell proliferation Source: Ensembl
Positive regulation of T cell receptor signaling pathway Source: UniProtKB
Regulation of apoptotic process Source: InterPro
Regulation of B cell differentiation Source: Ensembl
Regulation of T cell differentiation Source: Ensembl
Stimulatory C-type lectin receptor signaling pathway Source: Reactome
T cell costimulation Source: UniProtKB
T cell receptor signaling pathway Source: Reactome
Thymic T cell selection Source: Ensembl
TORC1 signaling Source: UniProtKB

Cellular Location

Cytoplasm; Membrane raft. Colocalized with DPP4 in membrane rafts.

Involvement in disease

B-cell expansion with NFKB and T-cell anergy (BENTA): An autosomal dominant condition characterized by onset in infancy of splenomegaly and polyclonal expansion of B cells, resulting in peripheral lymphocytosis. Affected individuals also show mild immune dysfunction, including some defective antibody responses and T-cell anergy. There may be a predisposition to the development of B-cell malignancy.
Immunodeficiency 11 A (IMD11A): An autosomal recessive primary immunodeficiency characterized by normal numbers of T and B-lymphocytes, but defective intracellular signaling. There is a block in B-cell differentiation with increased numbers of transitional B-cells and hypogammaglobulinemia, as well as decreased numbers of regulatory T-cells and defects in T-cell function.
Immunodeficiency 11B with atopic dermatitis (IMD11B): An autosomal dominant disorder of immune dysfunction characterized by onset of moderate to severe atopic dermatitis in early childhood. Some patients may have recurrent infections and other variable immune abnormalities. Laboratory studies show defects in T-cell activation, increased IgE, and eosinophilia.

PTM

Phosphorylation at Ser-559, Ser-644 and Ser-652 by PRKCB and PRKCQ leads to a shift from an inactive to an active form that activates the NF-kappa-B signaling.

Reimann, M., Schrezenmeier, J., Richter-Pechanska, P., Dolnik, A., Hick, T. P., Schleich, K., ... & Schmitt, C. A. (2021). Adaptive T-cell immunity controls senescence-prone MyD88-or CARD11-mutant B-cell lymphomas. Blood, The Journal of the American Society of Hematology, 137(20), 2785-2799.

Shi, X., Xia, S., Chu, Y., Yang, N., Zheng, J., Chen, Q., ... & Lin, J. (2021). CARD11 is a prognostic biomarker and correlated with immune infiltrates in uveal melanoma. Plos one, 16(8), e0255293.

Meitlis, I., Allenspach, E. J., Bauman, B. M., Phan, I. Q., Dabbah, G., Schmitt, E. G., ... & James, R. G. (2020). Multiplexed Functional Assessment of Genetic Variants in CARD11. The American Journal of Human Genetics, 107(6), 1029-1043.

Wang, W., Chang, X., Yao, W., Wei, N., Huo, N., Wang, Y., ... & Xiao, S. (2019). Host CARD11 inhibits Newcastle disease virus replication by suppressing viral polymerase activity in neurons. Journal of virology, 93(24), e01499-19.

Lork, M., Staal, J., & Beyaert, R. (2019). Ubiquitination and phosphorylation of the CARD11-BCL10-MALT1 signalosome in T cells. Cellular immunology, 340, 103877.

Holliday, M. J., Witt, A., Gama, A. R., Walters, B. T., Arthur, C. P., Halfmann, R., ... & Fairbrother, W. J. (2019). Structures of autoinhibited and polymerized forms of CARD9 reveal mechanisms of CARD9 and CARD11 activation. Nature communications, 10(1), 1-17.

Dorjbal, B., Stinson, J. R., Ma, C. A., Weinreich, M. A., Miraghazadeh, B., Hartberger, J. M., ... & Snow, A. L. (2019). Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. Journal of Allergy and Clinical Immunology, 143(4), 1482-1495.

Lu, H. Y., Bauman, B. M., Arjunaraja, S., Dorjbal, B., Milner, J. D., Snow, A. L., & Turvey, S. E. (2018). The CBM-opathies—a rapidly expanding spectrum of human inborn errors of immunity caused by mutations in the CARD11-BCL10-MALT1 complex. Frontiers in immunology, 9, 2078.

Bedsaul, J. R., Carter, N. M., Deibel, K. E., Hutcherson, S. M., Jones, T. A., Wang, Z., ... & Pomerantz, J. L. (2018). Mechanisms of regulated and dysregulated CARD11 signaling in adaptive immunity and disease. Frontiers in immunology, 9, 2105.

Ma, C. A., Stinson, J. R., Zhang, Y., Abbott, J. K., Weinreich, M. A., Hauk, P. J., ... & Milner, J. D. (2017). Germline hypomorphic CARD11 mutations in severe atopic disease. Nature genetics, 49(8), 1192-1201.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-CARD11 Recombinant Antibody (CBFYC-0811)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Rabbit Anti-CARD11 Recombinant Antibody (CBLC102-LY) (CAT#: CBMAB-C9704-LY)

Rabbit Anti-CARD11 Recombinant Antibody (1D12) (CAT#: CBMAB-C1310-CN)

Rabbit Anti-CARD11 Recombinant Antibody (EG479) (CAT#: CBMAB-EN543-LY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry